Fritextsökning
Innehållstyper
-
AI detects tumor disease – via voice recording
A short voice recording along with facial images – both analyzed with an AI algorithm – can make it possible to detect the rare tumour disease acromegaly and in...
-
Automate E2E Image Analysis Pipelines
ZEISS arivis Pro - Your End-to-End Scientific Image Analysis Software.
-
New drug to simplify treatment of hemophilia
A new type of treatment for hemophilia, which only needs to be administered every two months, has been approved by the U.S. Food and Drug Administration (FDA).
-
Conference recordings now available
Don't miss out on insights from leading experts.
-
DBB ventiler: Snabbare installationer och färre skarvar
Spirax Sarco Safebloc är en lösning med en unik platsbesparande design som innebär snabbare installation och färre skarvar. Spirax
-
ZEISS Quality Innovations at CONTROL
May 6-9, 2025 in Stuttgart.
-
Final assembly inspection of medical plastics
Technical paper by ZEISS Medical Industry Solutions.
-
Microscope and measuring machine in one
ZEISS O-INSPECT duo covers two essential applications in quality assurance.
-
Elevating 3D characterization with enhanced performance and efficiencies
Introducing the ZEISS VersaXRM 730 3D X-ray microscope.
-
Organize and Manage Digital Classrooms
Create engaging lessons with ZEISS Labscope Teacher.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...
-
High-tech companies are increasingly focusing on health
Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more about them advancing their positions,” says Anna Lefevre Skjöldebrand, CEO of Swedish Medtech....
-
Norway rejects national life science strategy – sees no need
The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.
-
FDA approves first non-opioid pain reliever in over 20 years
For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.
-
“A major energy boost for the entire cancer vaccine field”
The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...
-
LINK Medical recruits Swedish CEO
The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.
-
Marie Gårdmark: “What to expect from Trump’s second term?”
One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...
-
Anna Törner: “My quantified life”
“The expression ‘you can’t see the forest for the trees’ feels newly relevant in the context of wearables. One can easily get caught up in the idea that the mor...
-
First preterm infants study – a vital step for Neola
After years of developing an advanced lung monitoring system, Neola Medical has received some delightful news: permission to start its first clinical study on p...
-
Reliably gripping and turning small parts
The extremely compact rotary gripper module EHMD is the ideal choice in many life science applications where small objects need to be gripped and turned in conf...
-
She is CSL Behring's new Nordic General Manager
Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.
-
Pneumatics Makes a Technological Leap with Piezo
The first high-precision proportional valve terminal VTEP opens up new application areas
-
How the Foreign Office will promote Swedish life science exports
The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...
-
From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”
A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...